Cookie policy notice

By continuing to use this site you agree to our cookies policy below:
Since 26 May 2011, the law now states that cookies on websites can ony be used with your specific consent. Cookies allow us to ensure that you enjoy the best browsing experience.

This site is intended for health professionals only

At the heart of general practice since 1960

Fall in GP registrars deepens 'desperate' workforce crisis

NICE has published guidance on clopidogrel and modified-release dipyridamole for the secondary prevention of strokes and heart attacks.

In its technology appraisal, NICE ruled that patients who had had a stroke or heart attack, or who had been diagnosed with symptomatic peripheral arterial disease, should be prescribed the drugs in certain circumstances.

For patients who had suffered a stroke, NICE said MR dipyridamole should be used in combination with aspirin for two years from the most recent event.

NICE said clopidogrel should be used on its own within its licensed indications for patients who could not tolerate low-dose aspirin and who had either had a stroke or MI or had symptomatic peripheral arterial disease.

Primary Care Cardiovascular Society spokesman Dr John Pittard said it was wrong to restrict clopidogrel to aspirin-

intolerant patients. 'It's the

institute for cost evasion.'

Rate this article 

Click to rate

  • 1 star out of 5
  • 2 stars out of 5
  • 3 stars out of 5
  • 4 stars out of 5
  • 5 stars out of 5

0 out of 5 stars

Have your say